Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Maria E. Suarez-Almazor; Xerxes Pundole; Noha Abdel-Wahab; Douglas B. Johnson; Dipti Gupta; Ilya Glezerman; Tim Cooksley; Ronald Anderson; Ada Blidner; Jennifer Choi; Michael Dougan; Pamela Ginex; Monica Girotra; Vickie R. Shannon; Bernardo L. Rapoport

doi:10.1007/s00520-020-05710-8

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Maria E. Suarez-Almazor, Xerxes Pundole, Noha Abdel-Wahab, Douglas B. Johnson, Dipti Gupta, Ilya Glezerman, Tim Cooksley, Ronald Anderson, Ada Blidner, Jennifer Choi, Michael Dougan, Pamela Ginex, Monica Girotra, Vickie R. Shannon, Bernardo L. Rapoport^*

^*Corresponding author for this work

Dermatology

Research output: Contribution to journal › Article › peer-review

19 Scopus citations

Abstract

Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

Original language	English (US)
Pages (from-to)	6159-6173
Number of pages	15
Journal	Supportive Care in Cancer
Volume	28
Issue number	12
DOIs	https://doi.org/10.1007/s00520-020-05710-8
State	Published - Dec 2020

Funding

Professor BL Rapoport is supported by supported by the Cancer Association of South Africa (CANSA) and the National Research Foundation (NRF) of South Africa. Dr. I. Glezerman is supported by the NIH/NCI (Cancer Center Support Grant P30 CA008748). Professor BL Rapoport is supported by supported by the Cancer Association of South Africa (CANSA) and the National Research Foundation (NRF) of South Africa. Dr. I. Glezerman is supported by the NIH/NCI (Cancer Center Support Grant P30 CA008748). AW, XP, AB, RA, JC, TC, PG, DG RAG, and VRS have no conflict of interest to declare. MD reports grants from Novartis, other (SAB) from Neoleukin Therapeutics, personal fees from Partner Therapeutics, personal fees from Tillotts Pharma, and grants from Genentech, outside the submitted work. MG reports consultant work with Bristol Myers Squibb (BMS), and AstraZeneca, outside the submitted work. IG reports other (Stock Ownership) from Pfizer Inc., and personal fees from CytomX Inc., outside the submitted work. DBJ reports other (advisory board) from Array Biopharma, grants and other (advisory board) from BMS, other (advisory board) from Jansen, grants from Incyte, other (advisory board) from Merck, and other (advisory board) from Novartis, outside the submitted work. In addition, DBJ has a patent co-inventor on use of CTLA-4 agonist for IAEs pending. BLR reports personal fees and other (advisory board) from Merck and Co.; grants, personal fees, and other (advisory board) from BMS; grants, personal fees, and other (advisory board) from Roche South Africa; and personal fees and other (advisory board) from AstraZeneca, during the conduct of the study. MSA reports personal fees from Gilead, grants from Pfizer, and personal fees from Abbvie, outside the submitted work.

Keywords

Arthralgia
Arthritis
Cardiomyopathy
Corticosteroids
Immunomodulation agents
Myocarditis
Myositis
Other immunosuppressive agents
Polymyalgia

ASJC Scopus subject areas

Oncology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1007/s00520-020-05710-8

Fingerprint

Dive into the research topics of 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors'. Together they form a unique fingerprint.

Cite this

Suarez-Almazor, M. E., Pundole, X., Abdel-Wahab, N., Johnson, D. B., Gupta, D., Glezerman, I., Cooksley, T., Anderson, R., Blidner, A., Choi, J., Dougan, M., Ginex, P., Girotra, M., Shannon, V. R., & Rapoport, B. L. (2020). Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer, 28(12), 6159-6173. https://doi.org/10.1007/s00520-020-05710-8

@article{8ff7aa2d585a42c2bc59ee8c9fa0ba12,

title = "Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors",

abstract = "Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.",

keywords = "Arthralgia, Arthritis, Cardiomyopathy, Corticosteroids, Immunomodulation agents, Myocarditis, Myositis, Other immunosuppressive agents, Polymyalgia",

author = "Suarez-Almazor, {Maria E.} and Xerxes Pundole and Noha Abdel-Wahab and Johnson, {Douglas B.} and Dipti Gupta and Ilya Glezerman and Tim Cooksley and Ronald Anderson and Ada Blidner and Jennifer Choi and Michael Dougan and Pamela Ginex and Monica Girotra and Shannon, {Vickie R.} and Rapoport, {Bernardo L.}",

note = "Publisher Copyright: {\textcopyright} 2020, Springer-Verlag GmbH Germany, part of Springer Nature.",

year = "2020",

month = dec,

doi = "10.1007/s00520-020-05710-8",

language = "English (US)",

volume = "28",

pages = "6159--6173",

journal = "Supportive Care in Cancer",

issn = "0941-4355",

publisher = "Springer Verlag",

number = "12",

}

Suarez-Almazor, ME, Pundole, X, Abdel-Wahab, N, Johnson, DB, Gupta, D, Glezerman, I, Cooksley, T, Anderson, R, Blidner, A, Choi, J, Dougan, M, Ginex, P, Girotra, M, Shannon, VR & Rapoport, BL 2020, 'Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors', Supportive Care in Cancer, vol. 28, no. 12, pp. 6159-6173. https://doi.org/10.1007/s00520-020-05710-8

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. / Suarez-Almazor, Maria E.; Pundole, Xerxes; Abdel-Wahab, Noha et al.
In: Supportive Care in Cancer, Vol. 28, No. 12, 12.2020, p. 6159-6173.

Research output: Contribution to journal › Article › peer-review

TY - JOUR

T1 - Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

AU - Suarez-Almazor, Maria E.

AU - Pundole, Xerxes

AU - Abdel-Wahab, Noha

AU - Johnson, Douglas B.

AU - Gupta, Dipti

AU - Glezerman, Ilya

AU - Cooksley, Tim

AU - Anderson, Ronald

AU - Blidner, Ada

AU - Choi, Jennifer

AU - Dougan, Michael

AU - Ginex, Pamela

AU - Girotra, Monica

AU - Shannon, Vickie R.

AU - Rapoport, Bernardo L.

PY - 2020/12

Y1 - 2020/12

N2 - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

AB - Immune checkpoint inhibitors (ICIs) have emerged as the newest pillar of cancer treatment. Immune-mediated toxicities, stemming from increased activity within the T cell lineage, range from asymptomatic or mild complications to those that are fulminant and potentially fatal. Although they are of variable occurrence, cardiovascular, rheumatic, and renal immune-mediated toxicities are among the most serious of these adverse events. We present MASCC recommendations with respect to the workup and management of cardiovascular, rheumatic, and renal immune-mediated toxicities with a focus on presentations that require treatment with immunomodulating agents.

KW - Arthralgia

KW - Arthritis

KW - Cardiomyopathy

KW - Corticosteroids

KW - Immunomodulation agents

KW - Myocarditis

KW - Myositis

KW - Other immunosuppressive agents

KW - Polymyalgia

UR - http://www.scopus.com/inward/record.url?scp=85089896593&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85089896593&partnerID=8YFLogxK

U2 - 10.1007/s00520-020-05710-8

DO - 10.1007/s00520-020-05710-8

M3 - Article

C2 - 32856212

AN - SCOPUS:85089896593

SN - 0941-4355

VL - 28

SP - 6159

EP - 6173

JO - Supportive Care in Cancer

JF - Supportive Care in Cancer

IS - 12

ER -

Suarez-Almazor ME, Pundole X, Abdel-Wahab N, Johnson DB, Gupta D, Glezerman I et al. Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors. Supportive Care in Cancer. 2020 Dec;28(12):6159-6173. doi: 10.1007/s00520-020-05710-8

Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of immune-mediated cardiovascular, rheumatic, and renal toxicities from checkpoint inhibitors

Abstract

Funding

Keywords

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this